Vaccines against Vector-borne Diseases
Vaccines that target blood-feeding disease vectors, such as mosquitoes and ticks, have the potential to protect against the many diseases caused by vector-borne pathogens. Vector-borne diseases are among the most complex of all infectious diseases to prevent and control. Vector- borne diseases, most of which are transmitted in and around the home, are best controlled by a combination of vector control (use of public health insecticides on bednets, or by spraying), medicines and vaccines.
Historically, successful vector-borne disease prevention resulted from management or elimination of vector populations. Malaria was driven out of the USA and most of Europe in this way. Where vector control has been consistently applied in the past, the results have been dramatic, especially with early efforts to control malaria by spraying the inside surfaces of houses with insecticides. Indoor Residual Spraying (IRS) and long-lasting insecticide treated bednets have been very effective over the last 10 years and are widely regarded as one of the main contributors to the more than 1 million lives saved.
In contrast to expenditure and effort on medicine, diagnostic and vaccine development, relatively little attention was given to vector control in the past. The foresighted establishment of IVCC in 2005, with a grant from the Bill and Melinda Gates Foundation began the process of bringing Vector Control into the mainstream strategy for future eradication of malaria and other vector-borne diseases.
- Zika Virus
- Zika Virus
- Malaria
- Dengue
- Chikungunya
- Yellow fever
- Lyme disease
- Japanese encephalitis
- Leishmaniasis
Related Conference of Vaccines against Vector-borne Diseases
9th International Conference on Vaccines, Immunology and Clinical Trials
Vaccines against Vector-borne Diseases Conference Speakers
Recommended Sessions
- Cancer Vaccines and Immunotherapy
- Childhood and Maternal Vaccines
- DNA Vaccines
- Hepatitis Vaccines
- HIV/AIDS Vaccines
- HPV Vaccines
- Human Preventive & Therapeutic Vaccines
- Human Vaccines - Infectious & Non Infectious Diseases
- Immunology/Animal Models
- Mucosal Vaccines
- Next-Generation Vaccines Delivery Technologies
- Plant-based Vaccines
- Travel Immunization
- Vaccine Adjuvants
- Vaccine Research & Development
- Vaccine Safety & Efficacy
- Vaccines against Vector-borne Diseases
- Vaccines against Viral & Bacterial Diseases
- Vaccines Business Development
- Vaccines for Older Adults
- Vaccines for Respiratory Diseases
- Veterinary Vaccines
Related Journals
Are you interested in
- Adjuvants and Immunopotentiators - VACCINE CONGRESS 2025 (Japan)
- Adult and Elderly Vaccination Strategies - VACCINE CONGRESS 2025 (Japan)
- Advancements in Vaccine Research and Development - Vaccines R&D 2026 (France)
- Advances in Pediatric Vaccines - Vaccines R&D 2026 (France)
- Adverse reactions to the vaccination - Vaccines Congress-2025 (Canada)
- AI and Data Science in Vaccine Discovery - VACCINE CONGRESS 2025 (Japan)
- Antimicrobial Resistance (AMR) - VACCINES WORLD 2025 (Germany)
- Antimicrobial Resistance and Vaccines - VACCINE CONGRESS 2025 (Japan)
- Antinatal vaccinations - Vaccines Congress-2025 (Canada)
- Bioprocessing and Manufacturing - VACCINES WORLD 2025 (Germany)
- Booster Doses and Heterologous Vaccine Regimens - VACCINE CONGRESS 2025 (Japan)
- Cancer Vaccines and Immunotherapy - VACCINES WORLD 2025 (Germany)
- Cancer Vaccines and Immunotherapy - VACCINE CONGRESS 2025 (Japan)
- Clinical Trials - VACCINES WORLD 2025 (Germany)
- Clinical Trials Design and Methodologies - Vaccines R&D 2026 (France)
- Conjugate Vaccine - VACCINES WORLD 2025 (Germany)
- Conjugated and combination vaccinations - Vaccines Congress-2025 (Canada)
- Coronavirus (COVID-19) & Pandemic Vaccines - VACCINES WORLD 2025 (Germany)
- Corporate Innovation, Sponsorship & Exhibition - VACCINE CONGRESS 2025 (Japan)
- COVID-19 Vaccine Impact and Learnings - VACCINE CONGRESS 2025 (Japan)
- Creation and development of vaccines - Vaccines Congress-2025 (Canada)
- DNA, RNA & SYNTHETIC VACCINES - Vaccines Congress-2025 (Canada)
- DNA-RNA Vaccines - VACCINES WORLD 2025 (Germany)
- Emerging and Re-Emerging Diseases - VACCINES WORLD 2025 (Germany)
- Emerging Infectious Diseases and Vaccine Development - Vaccines R&D 2026 (France)
- Ethical Considerations in Vaccine Development and Distribution - Vaccines R&D 2026 (France)
- Fungal/Bacterial/Viral/Parasitic/STD Vaccines - VACCINES WORLD 2025 (Germany)
- Global Immunization Programs and Policy - VACCINE CONGRESS 2025 (Japan)
- Global Immunization Strategies and Policy - Vaccines R&D 2026 (France)
- HIV , Malaria & TB vaccines - Vaccines Congress-2025 (Canada)
- HIV Vaccines - VACCINES WORLD 2025 (Germany)
- Immune Profiling - VACCINES WORLD 2025 (Germany)
- Immunology of Infectious Diseases - Vaccines R&D 2026 (France)
- Immunotherapy and Personalized Medicine - Vaccines R&D 2026 (France)
- Infectious and Non-Infectious Diseases - VACCINES WORLD 2025 (Germany)
- Infectious Disease Vaccines - VACCINE CONGRESS 2025 (Japan)
- Influenza and Respiratory Vaccines - VACCINES WORLD 2025 (Germany)
- Innovations in Vaccine Cold Chain and Storage - Vaccines R&D 2026 (France)
- Manufacturing, Supply Chain, and Distribution - VACCINE CONGRESS 2025 (Japan)
- Nanotechnology in Vaccine Delivery - VACCINE CONGRESS 2025 (Japan)
- Next-Generation Vaccine Technologies - VACCINE CONGRESS 2025 (Japan)
- Pediatric and Neonatal Vaccines - VACCINE CONGRESS 2025 (Japan)
- rDNA technology in vaccine development - Vaccines Congress-2025 (Canada)
- Recent advances in vaccine development - Vaccines Congress-2025 (Canada)
- Regulatory Approaches in Vaccine Development - Vaccines R&D 2026 (France)
- Role of Adjuvants in Vaccine Efficacy - Vaccines R&D 2026 (France)
- Role of AI and Big Data in Vaccine Research - Vaccines R&D 2026 (France)
- The COVID-19 vaccine's next-generation RNA platforms and mRNA - Vaccines Congress-2025 (Canada)
- Thermo Stabilized Vaccines - VACCINES WORLD 2025 (Germany)
- Toxoid vaccination - Vaccines Congress-2025 (Canada)
- Translational Immunology and Vaccine Development - Vaccines R&D 2026 (France)
- Vaccine Adjuvants - VACCINES WORLD 2025 (Germany)
- Vaccine and Vaccination - Vaccines Congress-2025 (Canada)
- Vaccine Delivery Systems: Innovations and Challenges - Vaccines R&D 2026 (France)
- Vaccine Development for Cancer Immunotherapy - Vaccines R&D 2026 (France)
- Vaccine Development for Vector-Borne Diseases - Vaccines R&D 2026 (France)
- Vaccine efficiency and well-being - Vaccines Congress-2025 (Canada)
- Vaccine Equity and Access in Low-Resource Settings - Vaccines R&D 2026 (France)
- Vaccine for infectious illnesses in humans - Vaccines Congress-2025 (Canada)
- Vaccine Hesitancy and Public Perception - Vaccines R&D 2026 (France)
- Vaccine Manufacturing and Distribution - Vaccines R&D 2026 (France)
- Vaccine manufacturing technologies - Vaccines Congress-2025 (Canada)
- Vaccine Production, Supply & Logistics - VACCINES WORLD 2025 (Germany)
- Vaccine Research and Clinical trials - Vaccines Congress-2025 (Canada)
- Vaccine Research and Development - VACCINES WORLD 2025 (Germany)
- Vaccine Research Ethics and Regulations - VACCINE CONGRESS 2025 (Japan)
- Vaccine Safety and Pharmacovigilance - Vaccines R&D 2026 (France)
- Vaccine Safety and Pharmacovigilance - VACCINE CONGRESS 2025 (Japan)
- Vaccine Safety, Efficacy & Regulatory Affairs - VACCINES WORLD 2025 (Germany)
- Vaccines against non-traditional illnesses - Vaccines Congress-2025 (Canada)
- VACCINES FOR CANCER - Vaccines Congress-2025 (Canada)
- Veterinary and Zoonotic Vaccines - VACCINE CONGRESS 2025 (Japan)
- Veterinary Vaccine - VACCINES WORLD 2025 (Germany)
- Workshops and Poster Sessions - VACCINE CONGRESS 2025 (Japan)
- Zika Virus vaccines - Vaccines Congress-2025 (Canada)